TriAxis Biosciences

Name: TriAxis Biosciences
Address: 141 E 5600 S, Murray, UT, 84107, US
Telephone: +5712082256
Price range: $$$

Home
United States
Murray, UT
TriAxis Biosciences

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from TriAxis Biosciences, Biotechnology company, 141 E 5600 S, Murray, UT.

TriAxis Biosciences is a Utah-based life sciences company focused on antimicrobial resistance, wastewater genomics, bioinformatics, and scientific innovation to advance public health through research, data-driven solutions, and strategic partnerships.

08/25/2026

We are delighted to welcome Dr. Liszhen (Michelle) Snyder, PhD, as Co-Founder of TriAxis Biosciences!

Dr. Snyder brings extensive expertise in bacterial genomics, next-generation sequencing, and microbiology. Her scientific background, combined with her early experience in healthcare, has shaped her commitment to advancing research with meaningful public-health impact.

Her leadership and interdisciplinary perspective will be invaluable as TriAxis Biosciences continues developing innovative solutions to address critical challenges in infectious disease and public health.

Please join us in welcoming Michelle to the team!

07/28/2026

We’re Live! 🚀

We’re excited to announce that the TriAxis Biosciences website is officially live.

TriAxis is building AI-powered bioinformatics solutions that transform complex biological and environmental data into actionable public health intelligence.

This launch represents an important milestone in our journey, and we’re grateful to everyone who has supported us along the way.

We’re just getting started, and we’re excited to share more in the months ahead.

🌐 Explore our website and follow our journey: www.triaxisbiosciences.com

07/24/2026

In 2016, a woman in Nevada died from an infection resistant to all 26 antibiotics her doctors had.

Every single one. Nothing worked.

At the time, it made national news. A medical horror story. A rare, terrifying outlier.

Here’s the problem: it’s not an outlier anymore.

The gene behind her infection called NDM disables carbapenems, the antibiotics we save for when everything else fails. CIDRAP reported this week that infections carrying NDM rose 461% between 2019 and 2023 across US surveillance labs. These “nightmare bacteria” already kill 30 to 50% of the people they infect.

And the dead-ends keep coming. Just last year, clinicians described a critically ill man whose Pseudomonas infection resisted even cefiderocol one of our newest last-line drugs before progressing to multi-organ failure.

Nine years after Nevada, we are still running out of antibiotics. Only now it’s a trend, not a headline.

Here’s what keeps us up at night about it 👇

1. We often can’t even see it.
Doctors can only fight NDM if they know it’s there but many hospital labs lack the testing to detect it. You cannot treat what you cannot see.

2. It doesn’t stay in one bug.
NDM rides on plasmids tiny loops of DNA that jump freely between bacterial species. We’re not chasing one pathogen. We’re chasing a gene that hops hosts.

3. It’s already outside the hospital.
AMR is called the silent pandemic because most transmission happens outside healthcare. A new study of 163 US wastewater sites found NDM spreading in communities, tracking with poverty, overcrowding, and lack of insurance.

So the danger isn’t just in the ICU.

It’s in the water. In the community. Weeks before it ever shows up as a clinical case. That’s the entire reason TriAxis Biosciences is working on.

We’re building wastewater-based genomic surveillance to catch emerging resistance threats early including the mobile genes that slip right past conventional testing.

Because here’s the part nobody wants to hear:

There is no cure for AMR. No endgame. No final victory. Resistance will always emerge to whatever we invent next. In a war with no finish line, seeing the enemy first isn’t a luxury. It’s the only advantage we get.

If you work in public health, biotech, or policy: what’s actually stopping us from making genomic AMR surveillance a national baseline? We would genuinely like to hear it. 👇

07/17/2026

We’re proud to share that our Founder & CEO, Sunil Pandey, has joined the HITLAB Breakthrough Technology Alliance (BTA) as an Executive Member.

This milestone strengthens TriAxis Biosciences’ mission to advance AI-driven solutions for antimicrobial resistance surveillance and public health. We look forward to collaborating with global innovators, building strategic partnerships, and accelerating the impact.

Thank you, HITLAB, for the opportunity!

07/13/2026

We are honored to welcome Dr. Jennifer L. Salerno, PhD, to the Advisory Board of TriAxis Biosciences.

Dr. Salerno brings deep expertise in environmental microbiology, microbial ecology, marine biology, ecosystem health, and interdisciplinary science. Her scientific background and leadership will provide valuable guidance as TriAxis Biosciences continues advancing innovation at the intersection of bioscience, environmental health, public health, and technology.

Beyond her research, Dr. Salerno is also deeply engaged in science communication and interdisciplinary work at the intersection of science, policy, and diplomacy. She previously worked on coastal and ocean issues in the U.S. House of Representatives as a NOAA Sea Grant Knauss Fellow and served as an AAAS Science and Technology Policy Fellow at the U.S. Department of State, Bureau of East Asian and Pacific Affairs, Office of Economic Policy.

In that role, she advised and coordinated U.S. policy on science and technology, energy, and oceans issues across federal agencies and within the Asia-Pacific Economic Cooperation framework.

Her unique combination of scientific expertise, policy experience, and global perspective will be an incredible asset to TriAxis Biosciences.
Welcome to the team, Dr. Salerno. We are grateful for your guidance and excited to work together.

07/10/2026

Out of 1,277 global applications reviewed by 201 expert judges, it is truly an honor to have our innovation recognized for its potential real-world impact in healthcare and technology.

We are especially grateful that TriAxis Biosciences received the Audience Choice Award at the HITLAB World Cup Innovation Pitch Day 2026. This recognition is a meaningful milestone for our team as we continue advancing innovation in digital health, AI, and public health.

06/26/2026

We are honored to welcome Dr. Patrick M. Gillevet to the TriAxis Biosciences Advisory Board.

Dr. Gillevet brings outstanding expertise in microbiome analysis, genomics, bioinformatics, molecular ecology, and systems biology. As a professor, researcher, and leader in microbiome science, his work has advanced our understanding of microbial communities in human health, environmental ecosystems, and complex biological systems.

His experience strongly aligns with TriAxis Biosciences’ mission to advance data-driven biology, wastewater-based surveillance, and public health innovation.

Welcome to the team, Dr. Gillevet. We are excited and grateful to have your guidance as we continue building TriAxis Biosciences.

06/25/2026

We are honored to welcome Dr. Tae Seok Moon to the TriAxis Biosciences Advisory Board.

Dr. Moon brings deep expertise in systems and synthetic biology, with a vision to solve global challenges in agriculture, the environment, manufacturing, and human health through engineering biology.

His scientific leadership and innovative perspective strongly align with TriAxis Biosciences’ mission to advance data-driven biology and public health solutions.

Welcome to the team, Dr. Moon. We are excited to learn from your expertise and work together toward meaningful impact.

06/24/2026

We were proud to represent TriAxis Biosciences at Startups Pitch to Investors in Palo Alto, CA.

It was a valuable opportunity to present our vision, connect with investors and innovators, and build relationships that can help advance our work in genomics, bioinformatics, and public-health innovation.

Thank you to everyone who took the time to connect, share feedback, and support emerging biotech innovation. We are energized by the conversations and excited about what comes next.

06/22/2026

We are excited to share that TriAxis Biosciences will be presenting at Startups Pitch to Investors in Palo Alto, CA on June 23, 2026.

This is a great opportunity for us to introduce our vision, connect with investors and innovators, and share how TriAxis is working at the intersection of genomics, bioinformatics, AI, and public health innovation.

We look forward to engaging with the Palo Alto startup and investor community and continuing to build meaningful partnerships around data-driven solutions for public health.

📍 Palo Alto, CA
📅 June 23, 2026

Address

141 E 5600 S
Murray, UT
84107

Telephone

+5712082256

Website

https://www.triaxisbiosciences.com/

Alerts

Be the first to know and let us send you an email when TriAxis Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to TriAxis Biosciences:

Want your business to be the top-listed Business in Murray?